The effects of long-acting nitrates on 5-year cardiac events of patients with coronary thrombolytic therapy for acute myocardial infarction

Internal Medicine

Volumn 39, Issue 11, 2000, Pages 877-884

  Nagao, Ken ^a,b   Kanmatsuse, Katsuo ^b   Ooiwa, Kouji ^b   Satou, Kazuyosi ^b   Watanabe, Ikuyoshi ^b   Yamasita, Makoto ^b   Kikushima, Kimio ^b  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SURUGADAI NIHON UNIVERSITY HOSPITAL   (Japan)

Author keywords

Acute coronary syndrome; Nitroglycerin; Prognosis; Secondary prevention

Indexed keywords

NITRIC ACID DERIVATIVE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; FEMALE; FIBRINOLYTIC THERAPY; HEART DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 0033764395     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.39.877     Document Type: Article

References (24)

1. Fung HL, Chung SJ, Bauer JA, Chong S, Kowaluk EA. Biochemical mechanism of organic nitrate action. Am J Cardiol 70 (suppl 5): 4B-10B, 1992.
2. Bussmann WD, Passek D, Seidel W, Kaltenbach M. Reduction of CK and CK-MB indexes of infarct size by intravenous nitroglycerin. Circulation 63: 615-622, 1981.
3. Jugdutt BI, Warnica JW. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications: effect of timing, dosage, and infarct location. Circulation 78: 906-919, 1988. Published erratum appears in Circulation 79: 1151, 1989.
4. Yusuf S, Collins R, MacMahon S, Peto R. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet 1: 1088-1092, 1988.
5. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Commitee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 28: 1328-1428, 1996.
6. GISS (Gruppo Italiano per lo studio della Sopravvivenza nell'Infarto Miocardico)-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction: Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 343: 1115-1122, 1996.
7. ISIS-4 (Fourth International Study of Infarct Survival). A randomized factrial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 345: 669-685, 1995.
8. FDA'S Cardiovascular & Renal Drugs Advisory Commitee. Oral anti-anginal nitrates should be indicated only for single, not chronic, use in absence of long-term data, FDA cardio-renal drugs advisory CMTE concludes. FDA Reports (The Pink Sheet). June 7, 1993.
9. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase 1: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 76: 142-154, 1987.
10. Cohn PF, Maddox DE, Holman BL, See JR. Effect of coronary collateral vessels on regional myocardial blood flow in patients with coronary artery disease. Am J Cardiol 46: 359-364, 1980.
11. Norris RM, Whithock RM, Barratt-Boyes C, Small CW. Clinical measurement of myocardial infarct size; modification of a method for the estimation of total creatine phosphokinase release after myocardial infarction. Circulation 51: 614-620, 1975.
12. Oscharoff A. Pentaerythritol tetrantirate as adjunct therapy in the immediate postinfarction period. Angiology 15: 505-514, 1964.
13. Mellen HS, Goldberg HS, Friendman HF. Therapeutic effects of pentaerythritol tetranirate in the immediate post myocardial infarction period. N Engl J Med 276: 319-322, 1967.
14. Newell DJ. Pentaerythritol tetranitrate (sustained action) in acute myocardial infarction. Br Heart J 32: 16-20, 1970.
15. Fitzgerald LJ, Bennett ED. The effects of oral isosorbide mononitrate on mortality following acute myocardial infarction: a multicenter study. Eur Heart J 11: 120-126, 1990.
16. The ESPRIM trial. Short-term treatment of acute myocardial infarction with molsidomine. (Europen Study of Prevention of infarct with Molsidomin group) Lancet 344: 91-97, 1994.
17. Ishikawa K, Kanamasa K, Ogawa I, et al. Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction. Jpn Circ J 60: 779-788, 1996.
18. Needleman P, Johnson EM Jr. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther 184: 709-715, 1973.
19. Packer M, Lee WH, Kesler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 317: 799-804, 1987.
20. Mangione NJ, Glasser SP. Phenomenon of nitrate tolerance. Am Heart J 128: 137-146, 1994.
21. Brugger W, Imhof P, Muller P, Moser P, Reubi F. Effect of nitroglycerin on blood rheology in healthy subjects. Eur J Clin Pharmacol 29: 331-336, 1985.
22. Watanabe H, Kakihana M, Ohtsuka S, Emomoto T, Yasui K, Sugishita Y. Platelet cyclic GMP. A potentially useful indicator to evaluate the effects of nitroglycerin and nitrate tolerance. Circulation 88: 29-36, 1993.
23. Munzel T, Sayegh H, Freeman BA, Tarpey MH, Harison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance: A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 95: 187-194, 1995.
24. Thadani U, Maranda CR, Amsterdam E. Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate. Ann Interm Med 120: 353-359, 1994.